5467 |
TEER in Intermediate Risk Primary MR, Will It Follow the TAVR's Footsteps? |
Saibal Kar |
Apr. 08. 22 |
5466 |
TAVR for Asymptomatic Patients |
Phillippe Genereux |
Apr. 08. 22 |
5465 |
Leaflet Thrombosis, Is It Clinically Relevant? |
Duk-Woo Park |
Apr. 08. 22 |
5464 |
Long-Term Antithrombotic Strategy in PCI and AF Patients: Insights From the AFIRE Trial |
Satoshi Yasuda |
Apr. 08. 22 |
5463 |
DAPT Duration and NOAC Selection in the Afib-PCI Patient |
Renato D. Lopes |
Apr. 08. 22 |
5462 |
DAPT Study vs. Contemporary Trials: How Can We Reduce the Knowledge Gap? |
Robert W. Yeh |
Apr. 08. 22 |
5461 |
Optimal Antithrombotic Therapy After PCI in Asia (Japan): Why We Are Going Our Own Way? |
Takeshi Kimura |
Apr. 08. 22 |
5460 |
Role of CABG in Multivessel Disease |
Jack H. Boyd |
Apr. 08. 22 |
5459 |
Role of PCI in Multivessel CAD: What Do the New Guidelines Say? |
William F. Fearon |
Apr. 08. 22 |
5458 |
CABG Remains the Best Therapy for Most Patients With Left Main Disease |
John D. Puskas |
Apr. 08. 22 |